Apellis shareholders elect three Class II directors and ratify Deloitte as auditor at 2025 annual meeting

Apellis Pharmaceuticals, Inc.

Elected A. Sinclair Dunlop (54.1M for, 26.0M withheld), Alec Machiels (62.3M for, 17.8M withheld), Keli Walbert (76.95M for, 3.18M withheld) as Class II directors for three-year terms.
Ratified Deloitte & Touche as independent auditor for FY2025 with 103.9M for, 54.6K against, 116.2K abstain.
Approved non-binding advisory vote on named executive officer compensation: 75.9M for, 4.17M against, 59.9K abstain.
Recommended future say-on-pay votes every year (79.86M for 1-year); company will hold annual advisory votes.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.